HBM Holdings-B (02142) surged more than 6% in early trading, reaching HK$14.68 with a turnover of HK$8.02 million by the time of reporting. The uptick follows an announcement on November 19 that its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd. (Nona Biotechnology), has entered into a non-exclusive license agreement with Pfizer to advance preclinical antibody discovery for multiple potential disease indications. Under the agreement, Pfizer gains global access to Nona Biotechnology's proprietary HCAb platform for developing fully human heavy-chain-only antibodies. Nona Biotechnology will receive an upfront payment and is eligible for regulatory, clinical, and commercial milestone payments. Additionally, Nona Biotechnology may collaborate with Pfizer to leverage its HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering.